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A B S T R A C T
Investigator-initiated studies are invaluable, especially in fields that are not particularly of interest for the
pharmaceutical industry because they are either less profitable or concern special patient groups such as
pregnant women. However, designing, conducting, and completing an investigator-initiated randomised con-
trolled trial is challenging. Patients and physicians' preferences, ethics requirements, (international) legislation
and funding are all areas where such challenges are encountered. The Anticoagulants for LIving FEtuses (ALIFE)
2 study (NTR3361) is an example of an investigator initiated international multicenter trial that progresses
slowly, at least initially, as many challenges had to be overcome.
Here, we discuss the challenges we faced during the course of the ALIFE2 study up till now and we explain
how some of these challenges can be tackled or even avoided.
1. Background
In April 2010, results of the Anticoagulants for LIving FEtuses
(ALIFE) study were published [1]. A total of 364 women with un-
explained recurrent miscarriage (i.e. in the absence of evident causes of
miscarriage, such as abnormal parental karyotypes or uterine anoma-
lies) was randomised to either low-molecular-weight heparin (LMWH)
plus acetylsalicylic acid (ASA), ASA alone or placebo (for ASA). The
results indicated that neither the combination of LMWH and ASA, nor
ASA alone improved the likelihood of live birth in a subsequent preg-
nancy. Supported by data from two similar studies published around
the same time, these results changed guideline recommendations and
influenced clinical practice [2–4].
Although evidence for the lack of efficacy of anticoagulants in
women with unexplained recurrent miscarriage was provided by these
three independent studies, the question remains whether the subgroup of
women with recurrent miscarriage and inherited thrombophilia may
benefit from anticoagulants during pregnancy [5]. The association be-
tween inherited thrombophilia and pregnancy complications was pre-
viously investigated [6,7]. Homozygosity for Factor V Leiden or hetero-
zygosity for the prothrombin 20210A mutation were found to have a
significant association with early pregnancy loss, whereas late pregnancy
loss was most strongly associated with protein S deficiency and hetero-
zygosity for either Factor V Leiden or the prothrombin 20210A mutation.
In parallel, women with acquired thrombophilia, i.e. the presence of
antiphospholipid antibodies, are at an increased risk of recurrent mis-
carriage and other pregnancy complications [8,9]. As anticoagulants
increase the chance of live birth in women with acquired thrombophilia,
physicians are tempted to extrapolate this to women with inherited
thrombophilia, and prescribe LMWH, ASA or both [10,11]. However, a
beneficial effect has not been proven for these women. A subgroup
analysis of 47 women with inherited thrombophilia in the ALIFE study
suggested a beneficial effect of LMWH plus ASA (relative risk of live birth
1.31, 95% confidence interval [CI] 0.74 to 2.33) and of ASA alone (re-
lative risk of live birth 1.22, 95% CI 0.69 to 2.16). This analysis was
underpowered to demonstrate an effect and results of our systematic
review further underlined the lack of data in this particular group of
women [5]. A recent meta-analysis of eight trials comparing LMWH to no
LMWH during pregnancy in women with inherited thrombophilia, also
including data from the ALIFE study, found no significant difference in
pregnancy loss rates between the LMWH and no LMWH treatment groups
(relative risk 0.81, 95%CI 0.55 to 1.19) [12]. This point estimate fa-
voring LMWH was lost if only multicenter studies were included in the
meta-analysis (relative risk 1.04, 95%CI 0.93 to 1.16).
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Treatment with anticoagulants may increase the risk of bleeding in
pregnancy or around delivery. Furthermore, it is burdensome, requires
daily subcutaneous injections and often causes delayed-type hy-
persensitivity skin reactions, itching and/or bruises [13,14]. Therefore,
evidence to justify anticoagulants for women with inherited thrombo-
philia and recurrent miscarriage is urgently required. Hence, results
from the currently ongoing ALIFE2 study, in which the effect of antic-
oagulants on live birth in women with recurrent miscarriage and in-
herited thrombophilia is evaluated, are anxiously awaited.
The importance of evidence obtained from randomised controlled
trials is undeniable and widely recognized. But conducting a clinical
trial involves time and effort and can be challenging at times. As for
most international multicenter investigator-initiated trials, the journey
from the drawing board to the actual set-up of the trial has been far
from a smooth ride and various obstacles had to be overcome.
Identifying and finding a solution for these obstacles has been key in
improving the recruitment rate. Here, we will discuss several of the
obstacles encountered for the ALIFE2 study and how they have been
tackled.
2. Experienced challenges and hurdles
2.1. Design, set-up and funding
The ALIFE2 study was designed with much attention to methodo-
logical aspects, such as the number and timing of previous miscarriages
(determining eligibility), the study design (a two- or three-armed trial,
open label or placebo-controlled), the trial intervention (LMWH, ASA or
both and dose thereof) and start of the intervention (pre- or post-
conceptional). The study proposal was subsequently presented to na-
tional and international experts in the field to further optimize the
design and also to raise interest for the study amongst colleagues, who
would later be requested to participate in the study.
The final study protocol is a two-armed, open-label randomised
controlled trial, in which pregnant women with two or more mis-
carriages (not necessarily consecutive and irrespective of timing of the
pregnancy loss) and inherited thrombophilia (Factor V Leiden, pro-
thrombin G20210A mutation, or deficiency of protein C, S or antith-
rombin), are randomised before the 7th week of pregnancy to either
LMWH (enoxaparin 40mg or equivalent dose of another LMWH, once
daily), or no intervention [15].
The primary efficacy outcome of the study is live birth, and sec-
ondary outcomes include bleeding, venous thromboembolism (VTE)
and obstetric complications [15].
Initial limited funding was acquired as part of a VIDI-grant (The
Netherlands Organization for Health Research and Development,
016.126.364). Additional funding was acquired by the UK (United
Kingdom) team from the University of Warwick as part of a Research
for Patient Benefit grant (RfPB) from the UK National Institute for
Health Research (NIHR) [PB-PG-1013-32011].
Compared to the previous ALIFE study - a national, multicenter trial
-, we anticipated recruitment to be more challenging because of the
restrictive inclusion criterion of the presence of inherited thrombophilia
in women with recurrent miscarriage. As inherited thrombophilia tests
are positive in approximately 15% of women with unexplained re-
current miscarriage, it was estimated that completing enrolment with
the required 400 women would be accomplished within 5 years, with
continued follow-up until the outcome of pregnancies 9months after
inclusion of the final study participant. For a detailed overview of the
study protocol and sample size considerations, we refer the reader to
the open access published ALIFE2 study protocol [15].
2.2. Inclusion and exclusion criteria
Definitions and nomenclature of recurrent miscarriage, including
timing of miscarriage, number of losses and whether or not the losses
were consecutive, vary widely internationally [16–18]. Although the
choice of two miscarriages as a diagnosis of recurrent miscarriage and
as the inclusion criterion for the study was criticized in the design phase
of the study, this did not lead to substantial delay or disagreement once
the protocol was finalized. Different views of colleagues regarding this
criterion were respected, as these merely reflect the lack of strong
evidence for either definition. Clarification of the rationale behind in-
vestigators' opinions appeared key in realizing a compromise of in-
cluding women with two or more, not necessarily consecutive, mis-
carriages. With proper explaining and reasoning, the use of different
definitions did not affect recruitment. The broad definition of recurrent
miscarriage used in the study (i.e. two or more miscarriages) enables
participation of clinics with a stricter definition of recurrent miscarriage
(i.e. three or more) to participate. An open discussion regarding the
definition is essential to create mutual understanding and positively
influence study participation.
2.3. Choice of study intervention
In the ALIFE2 study, enoxaparin 40mg injection once daily (or an
equivalent dose of another LMWH), is compared to standard pregnancy
surveillance (no intervention). The type of treatment and dose were
extensively discussed. A three-armed trial also including ASA was not
considered feasible as the number of participants needed would in-
crease from 400 to over 700.
For heparin, both the anticoagulant activity and anti-inflammatory
properties are thought to contribute to maintenance of pregnancy [19].
In addition, heparin promotes trophoblast differentiation in vitro [20].
For ASA, the mechanism of action in pregnancy is less clear. Un-
fractionated heparin needs to be administered at least twice daily,
whereas for LMWH a single daily dose is sufficient. As in a direct
comparison of LMWH and UFH (both combined with ASA, in women
with antiphospholipid syndrome) both appeared equally effective,
LMWH was considered more favorable than UFH [21]. Results of the
previously mentioned subgroup analysis in women with inherited
thrombophilia in the ALIFE study suggested a greater effect on live
birth of LMWH plus ASA when compared to ASA alone. Furthermore,
for women with antiphospholipid syndrome, there is no evidence that
ASA alone increases live birth rates after recurrent miscarriage [5]. This
knowledge, taken together with the fact that for clinical practice the
question whether LMWH is effective appears most pressing, led to
LMWH as the intervention of choice for the ALIFE2 study.
Enoxaparin 40mg or an equivalent was the dose decided upon after
consultation with many colleagues; both to verify that there was
agreement amongst peers on the scientific merit of the study, as well as
to make sure that colleagues would be willing to participate. The
clinicians' experience and/or preference as well as the availability per
type of LMWH may differ per country and the possibility to use dif-
ferent types of LMWH within study context allows for an easy switch to
another LMWH in case of side effects or logistics. Consensus on the dose
was not easily reached. A high dose (e.g. equivalent to or even higher
than 80mg enoxaparin) would infer a higher bleeding risk, but would
minimize the possibility that a (dose-dependent) beneficial effect of
LMWH would not become apparent in the trial. Using a low dose would
conversely be potentially associated with a lower bleeding risk, but a
negative trial outcome (i.e. no beneficial effect of LMWH) would not
settle the doubt that a higher dose could have been effective. However,
the LIVE-ENOX trial showed no additional benefit of 80mg enoxaparin
over 40mg enoxaparin in women with recurrent miscarriage [22].
2.4. Control group and concomitant medication
In the ALIFE2 study LMWH is compared to standard pregnancy
surveillance (no treatment). The use of a placebo (e.g. saline injections)
was considered in the design-phase. Compared to no treatment, placebo
use could affect participation positively as well as negatively, as both a
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50% chance of saline injections, as well as a 50% chance of open-label
no treatment may be reasons for women to refuse or cancel participa-
tion. An example of a successful randomised double-blind placebo-
controlled trial in the pregnant population was the recent PREFIX
study; a clinical trial evaluating enoxaparin for prevention of recurrent
miscarriage in nonthrombophilic women in 13 French hospitals [23].
Arguments in favor of a placebo-control include a potentially more
valid trial result and minimization of the risk of performance bias, i.e.
that systematic differences arise between the groups in the care that is
provided, in exposure to other factors, and in assessment of data in-
cluding bleeding [24]. The difficulties of manufacturing placebo in-
jections and the high costs associated with manufacturing and dis-
tribution were the most important arguments against the use of
placebo. An open-label design with standard pregnancy surveillance
(no treatment) as a comparator to LMWH was agreed upon, as for the
unequivocal primary outcome (live birth) a placebo effect was con-
sidered minimal. Furthermore, the protocol accounted for the im-
portant quality criterion of concealment of allocation [25].
In the initial protocol, the use of medication with anticoagulant
effects such as non-steroid anti-inflammatory agents and ASA was
prohibited. This was amended 19months after the start of the trial,
after an eligible woman with a history of pre-eclampsia was not in-
cluded because her treating physician wanted to prescribe ASA to re-
duce the risk of pre-eclampsia in her subsequent pregnancy. A head to
head comparison of LMWH versus no treatment, not contaminated by
any co-medication, will provide the most valid evidence. However, with
already few eligible patients we considered it undesirable that eligible
women would be excluded for this reason. As the number of included
women with a history of pre-eclampsia was anticipated to be low and
ASA use would be randomly distributed between the two treatment
groups, the scientific integrity of the trial did not appear to be jeo-
pardized, the protocol was amended as such: “Apart from the assigned
study medication, women are strongly discouraged to use antic-
oagulants or other medication that affects hemostasis, including non-
steroidal anti-inflammatory drugs (NSAID's)”.
At a low dose (≤150mg daily), ASA to lower the risk for recurrent
pre-eclampsia (at the discretion of the treating physician) is dis-
couraged but allowed. This is an example of how protocol amendments
can lead to increased enrolment, without compromising the validity of
the study.
2.5. Review board approval and multicenter dimensions
With the foundation for the design of the study laid amongst Dutch
and international colleagues, it was anticipated that the study could be
initiated in the principal center, (Amsterdam University Medical
Centers – location Academic Medical Center [AMC], the Netherlands)
and shortly thereafter in the other Dutch centers, where colleagues had
expressed their intention to participate. Unfortunately, reality proved
otherwise. First, the study had to be approved by the ethics committee
of the AMC. After initial submission on June 20th 2012, approval was
obtained on August 31st 2012 and a subsequent notification of no ob-
jection by the competent authority was obtained on November 12th
2012.
In the Netherlands, a new directive had just been installed, intended
to improve and speed-up medical-ethical review of multicenter studies
[26]. Whereas previously a new study protocol would have to pass the
review board of each participating center, this directive states that the
individual review boards in the Netherlands are all officially acknowl-
edged and that a positive decision of either one is applicable to all
centers. Once reviewed and approved by one ethics board, the execu-
tion of the study in another center should only be agreed upon by the
local board of directors. This appears a straight-forward procedure,
which according to an observational study decreased the median time
to approval from 118 days in centers that did not comply with the di-
rective, to 50 days in centers that did. In practice, however, the boards
did not comply with this new directive, and would not consent without
a full review of the submission by their own ethics board, which re-
sulted in substantial delays [27,28].
Initiating participation of an additional not initially listed center
thus implied collecting the necessary documents from the trial office or
lead physician concerned at that new center (varying between 3weeks
to several months), a request for ethical approval (typically obtained in
2 weeks), a request for board of directors' approval at the new center
(varying between 1.5 to several months) and preparing the initiation of
the study at the new center (1 week), proved to be extremely slow.
These multicenter dimensions become even more challenging when
international centers become involved. Additional funding is required,
local standard practice can differ from the initiating country, other legal
regulations apply and obtaining local ethics approval is subject to other
matters and restrictions than already encountered. On the other hand,
international participation will maximize recruitment and will poten-
tially increase the external validity of the study, as women with dif-
ferent backgrounds, ethnicity and cultures can be enrolled.
A great number of international colleagues were supportive re-
garding the ALIFE2 study. However, in parallel to the Netherlands,
several centers initially willing to participate, withdrew later; still
supportive of the study, but not able to or willing to cope with antici-
pated initiation difficulties. It is therefore again key to ensure com-
mitment of the center intended to participate in an early stage, before
time and effort are wasted if initially consenting partners refrain from
participation in a later stage. However, for those centers willing to
participate, perseverance will pay off in the end. With different au-
thorities and logistics involved, the road from pledging to participate to
local ethics approval to the actual first randomisation may take time in
our experience.
A new European regulation (no. 536/2014) installed with the aim to
harmonize assessment of applications for clinical trials was published in
May 2014 and was put into effect mid-2016 [29]. It states that the
medical and scientific aspects of the application will be jointly assessed
by all member states via one application, which has been a major im-
provement in the application procedure for new trials. However, as
national aspects such as privacy, insurance and research facilities of the
application still need to be assessed by each member state individually,
and local management boards of the centers should still approve the
execution of the study, this regulation may be subject to the same pitfall
as the Dutch directive. In any case, patience and persistence are es-
sential and will be rewarded.
2.6. Conducting research in the pregnant population
Pregnant women are considered a special population and the need to
obtain data on safety and efficacy of medication in pregnant women from
clinical trials is undeniable [30,31]. Counselling eligible patients for the
ALIFE2 study, in which the comparator arm is standard pregnancy sur-
veillance (i.e. no intervention), can be challenging in women who have
already experienced at least two prior pregnancy losses and are under-
standably adamant on preventing a subsequent miscarriage. Careful ex-
planation of what is already known on the topic, but more importantly
what evidence is still lacking, has proven to be essential. Additionally, a
close collaboration between treating physician, midwives and the preg-
nant women participating in the study has led to very few patients being
lost to follow-up in the ALIFE2 trial. In the UK an additional challenge
has been the thromboprophylaxis risk assessment that is done at
28weeks in routine antenatal care as per RCOG guidelines (https://
www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf). This
has meant some women randomised to standard care are given LMWH
after 28weeks. As the majority (99%) of pregnancy losses would have
occurred before 28weeks, that administration of LMWH after 28weeks
will have little effect on the primary outcome of live birth rate. The data
analysis will be intention to treat so those randomised to standard care,
but receiving LMWH from 28week will remain in the standard care arm.
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2.7. Factors influencing actual recruitment
Once a center can start recruiting, the actual inclusion rate is de-
pendent on the input and efforts of local investigators and trial nurses,
who are often engaged with multiple studies and clinical work.
Research has shown that the only factor truly contributing to recruit-
ment is a dedicated local principal investigator or dedicated research
staff who are convinced of the value of recruitment for clinical practice
[32]. Trial recruitment remains a complex process and considerable
variation in recruitment and retention rates in publicly funded trials has
been described previously [33]. An open trial design and reminding
non-responders by telephone were found to increase recruitment rates
in a recent Cochrane review, whereas optimizing the patient informa-
tion form had little or no effect on recruitment [34].
Here, the discrepancy between commercial pharmaceutical trials
and investigator-initiated studies such as ALIFE2 become apparent.
Pregnant women are often excluded from pharmaceutical trials because
of the pharmaceutical companies' concerns for liability.
This implies that the great majority of studies undertaken in preg-
nant women are investigator-initiated and the academic sponsors have
to bear the expenses of the high liability insurance fees. A pharma-
ceutical trial can provide recruitment fees as high as several thousand
euros per included patient, whereas the ALIFE2 study only offers an
inclusion fee of €250,- per completed case report form. This compen-
sation for the work of study personnel per randomised patient is far too
small to be considered as an incentive to take charge and proactively
recruit patients, or exploit trial coordination or reporting activities. The
inclusion rate of the study is therefore merely dependent on the com-
mitment and scientific enthusiasm of local investigators. With high
(clinical) workloads and numerous studies demanding efforts ALIFE2 is
not always top priority. Study organizers therefore need to realize that
identifying centers with dedicated (principal) investigators or trial of-
fices as potential participating centers is very important.
In Netherlands each site interested to participate in the study, was
asked to estimate the number of anticipated inclusions per year. In the
UK we asked each site to complete a feasibility questionnaire and es-
timate the number of positive inherited thrombophilia screens they had
per year. This approach has proven to be problematic because the
clinicians at the sites did not have access to this data and their estimates
were inaccurate.
However, newly started trials are often subject to the paradox that
once a trial has begun, the number of eligible patients is suddenly much
lower than the number initially anticipated. This phenomenon is known
as Lasagna's law, and appears to hold true for ALIFE2 as well [35]. We
observed considerable time between the date the site was activated and
the date of the first patient enrolled, varying from 6months to almost
2.5 years.
In the end of 2014, the results of the Thrombophilia in Pregnancy
Prophylaxis Study (TIPPS) were published. This was a multicenter open
label randomised trial that recruited 292 women with thrombophilia
(inherited or presence of antiphospholipid antibodies) who were at an
increased risk of VTE or placenta mediated complications. The rates of
pregnancy loss were similar in the dalteparin treated group (12 of 146
[8.2%]) and the no dalteparin group (10 of 143 [7.0%]), with a risk
difference of 1.2% (95% CI -4.9 to 7.3) [36]. Although the ALIFE2 study
is markedly different, one might speculate that the results of this study
may have temporarily damped investigator enthusiasm. Reassuringly,
we have noticed increased international interest in the study over time,
with the number of participating centers continuously expanding.
Needless to say, as many women with inherited thrombophilia and
recurrent pregnancy loss are prescribed LMWH in absence of evidence
and outside study participation, both “positive” as “negative” results of
the ALIFE2 will be of invaluable significance to clinical practice.
The Women and Child Health Research Consortium initially estab-
lished in 2003 after a grant from The Netherlands Organization for
Health Research and Development, is a renowned collaborative
initiative for multicenter research in the Netherlands. Since 2015, the
consortium is under the auspices of the Dutch Society of Obstetrics and
Gynecology. Over 70 medical centers have joined this initiative, which
provides unique logistics for the ALIFE2 study. Joining centers are ac-
customed to including patients in ongoing investigator-initiated studies.
Furthermore, results of consortium studies find their way to daily
practice more easily. However, the popularity of this network may
outgrow its capacity. With a limited number of trials, the collaborators
were dedicated to deploy themselves for others, but as more and more
investigators wish to benefit from the network and progressively more
studies are introduced, the network is at risk of becoming overstrained
and participants' focus returns to individual priorities rather than those
of the collaboration. This is a disadvantage for investigator-initiating
studies compared with pharmaceutical trials. It can be overcome by an
enthusiastic approach, involving education (making collaborators
aware of the need for enrolment, providing them with tips for execution
of the study), motivation (providing progress reports encouraging
contribution and possible addition of sub study questions) and help
with identifying barriers that are experienced in the local setting.
However, only such a continuous effort will render the study staying on
top of priorities. A reorganization of the Consortium in 2016 aimed for
a more efficient collaboration, but infers higher overhead costs for
participating studies.
2.8. Discrepancy between scientific evidence and current clinical practice
Although current guidelines state that there is no evidence of a
beneficial effect of LMWH on live birth in women with recurrent mis-
carriage and inherited thrombophilia and that treatment is burden-
some, expensive and associated with bleeding, some physicians tend to
employ a benefit-of-the-doubt practice and prescribe LMWH to their
patients [4,37–39]. However, LMWH should not be prescribed in
women with inherited thrombophilia for prevention of recurrent
pregnancy loss, as there is currently no evidence to support this practice
[12]. No recruitment or selective recruitment (only randomizing
women at perceived ‘low risk’, and routine prescribing LMWH to
others) does not serve the study and will not provide the evidence
needed. Furthermore, this practice provides women who are rando-
mised to no treatment with an opt-out option, securing their LMWH
prescription elsewhere. Education, counselling and discussing the dif-
ferent viewpoints regarding evidence is again key to overcome this
issue.
A problematic aspect is the cost of screening for inherited throm-
bophilia. With no currently known effective treatment leading inter-
national guidelines advise against thrombophilia screening in women
with recurrent pregnancy loss, unless in the context of research [38,39].
These guidelines and recommendations on thrombophilia screening
changed over the course of the ALIFE2 study. Although the research
exception is explicitly stated this has strongly affected recruitment rates
for the ALIFE2 study, as thrombophilia screening is no longer part of
current clinical practice in some participating centers or has led to
lowered enthusiasm in centers who were initially interested to parti-
cipated in the trial.
Approximately 7 patients need to be screened to identify one with
inherited thrombophilia [40]. Restrained by budget cuts even collea-
gues acknowledging the need for the study and willing to contribute
can recruit only limited numbers of patients as those eligible are not
identified because screening is not performed. Unless screening is per-
formed in the context of patient care, a much higher study budget in-
cluding costs of inherited thrombophilia screening of all women with
unexplained recurrent miscarriage would be needed to overcome this
problem.
Finally, once an eligible woman has been identified, she has to be
informed of the study and sign consent to be enrolled. Although this may
not sound as the greatest hurdle, the art of asking for informed consent is
not easily mastered. Especially for a study like ALIFE2, where women
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eligible for the study often are willing to do anything to improve their
chance of a successful pregnancy, they may refuse participation for
various reasons. Counselling is key and a good explanation of the study
burden and potential benefits, but also of the scientific reasons why the
study is designed and how only randomised trials will provide answers
on whether therapies are effective, appear useful tools. Furthermore,
some women consent to participation at a recurrent miscarriage con-
sultation, but are not yet pregnant. It is important to stay in touch with
these women, to ensure they remain aware of the study and are rando-
mised as soon as they have a positive pregnancy test.
In the ALIFE2 study we register patients who are eligible, awaiting
pregnancy and have signed informed consent. In this way, they can be
randomised swiftly upon a positive pregnancy test. Interestingly, al-
though women have declined participation for various reasons, so far in
the Netherlands no eligible participant has declined to participate be-
cause of the 50% chance of being allocated to no treatment. In the UK
recruitment is through NHS clinics, a small minority of women (< 2%)
have declined to participate because they wanted to get the LMWH
from the private sector. In the UK and North America, the striking
feature of setting up this trial is that there has been more reluctance
from clinicians than patients for this trial. The clinicians either believe
that LMWH does not prevent miscarriage in acquired thrombophilia
and thus they do not agree that the costs of thrombophilia screening is
justified so do not allow screening or conversely, clinicians believe that
LMWH does have a beneficial effect and prescribe LMWH with a posi-
tive screening result.
3. Current status of the ALIFE2 study
With the many obstacles identified and some overcome, there is also
good news. Since the official launch of the study and the enrolment of
the first participant on January 11 2013, the study is currently re-
cruiting in 50 centers in 8 countries (number of centers (n) in the
Netherlands n=8, United Kingdom n=35, United States of America
n=2, Canada n=1, Australia n=1, Austria n= 1, Belgium n=1
and Slovenia n= 1). After obtaining funding (NIHR grant), the team at
the University of Warwick set up the UK-ALIFE2 team alongside the NL-
ALIFE2 team. The UK-team plans to recruit approximately 300 parti-
cipants in the UK and the NL-team will coordinate all other
participating (international) centers for the remaining 100 recruit-
ments. Evaluating the enrolment rate per month, we have experienced
an increase to approximately 5 randomizations per month in the past
4months. As of January 31st 2020, a total of 275 women have been
randomised in the trial, with an additional 118 registered eligible
women who have provided informed consent and are awaiting preg-
nancy (Fig. 1).
Doubling of the number of participating centers, increasing aware-
ness of the study and more involved collaboration between colleagues
have doubled the enrolment rate. As of 2016, the ALIFE2 study is en-
dorsed by INVENT-VTE, an international network established in 2015
aiming to accelerate clinical research in VTE [41]. With additional
funding for participation of the UK obtained, 13 centers currently in set
up and interest for the study is increasing globally, recruitment rates are
expected to increase further within the near future. This increasing
number of participating centers will not only add to the recruitment
rate, but hopefully also improve dissemination and implementation of
the study results, once obtained [42].
4. Conclusion
Designing and executing a multicenter trial is a huge operation,
even if the trial addresses a clear gap of evidence and is broadly sup-
ported by clinicians and patients. This is especially true for investigator-
initiated trials with limited funding. However, conducting such trials
remains the only way forward on the road towards more evidence.
Laying a solid foundation for the study amongst colleagues who will be
requested to participate, in advance of the study, identifying those
centers with dedicated investigators or trial offices, early recruitment of
potential participating centers, and a constant and enthusiastic pursuit
are key elements for success.
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